Table 1.
Patient demographics and disease characteristics for Patients with Stage IVC Non-OPSCC. RT: radiotherapy; CT: chemotherapy; CRT: chemoradiotherapy; NOS: not otherwise specified.
| HPV Negative | HPV Positive | All | p-value | |
|---|---|---|---|---|
| Total patients | 494 | 214 | 708 | |
| Age, years | <0.001 | |||
| Median (range) | 64 (35-90) | 59 (30-90) | 62 (30-90) | |
| Mean (Std. Dev.) | 63.9 (11.0) | 60.3 (9.9) | 62.8 (10.8) | |
| Tumor Size (mm) | 0.78 | |||
| Median (range) | 38 (1-100) | 38 (4-81) | 38 (1-100) | |
| Mean (Std. Dev.) | 39.3 (18.6) | 38.2 (16.0) | 39.0 (17.9) | |
| Age | <0.001 | |||
| <65 | 260 (52.6) | 147 (68.7) | 407 (57.5) | |
| ≥65 | 234 (47.4) | 67 (31.3) | 301 (42.5) | |
| Sex | <0.01 | |||
| Male | 384 (77.7) | 186 (86.9) | 570 (80.5) | |
| Female | 110 (22.3) | 28 (13.1) | 138 (19.5) | |
| Race | 0.12 | |||
| White | 370 (74.9) | 180 (84.1) | 550 (77.7) | |
| Black | 80 (16.2) | 20 (9.4) | 100 (14.1) | |
| Hispanic | 24 (4.9) | 10 (4.7) | 34 (4.8) | |
| Asian/Pacific islander | 10 (2.0) | 2 (0.9) | 12 (1.7) | |
| Other | 9 (1.8) | 2 (0.9) | 11 (1.6) | |
| Unknown | 1 (0.2) | 0 (0.0) | 1 (0.1) | |
| Year of Diagnosis | 0.08 | |||
| 2010 | 63 (12.8) | 22 (10.3) | 85 (12.0) | |
| 2011 | 118 (23.9) | 43 (20.1) | 161 (22.7) | |
| 2012 | 153 (31.0) | 58 (27.1) | 211 (29.8) | |
| 2013 | 160 (32.4) | 91 (42.5) | 251 (35.5) | |
| Charlson/Deyo Comorbidity Score | 0.05 | |||
| 0 | 336 (68.0) | 165 (77.1) | 501 (70.8) | |
| 1 | 114 (23.1) | 36 (16.8) | 150 (21.2) | |
| ≥ 2 | 44 (8.9) | 13 (6.1) | 57 (8.1) | |
| Insurance Type | <0.001 | |||
| Private | 118 (23.9) | 95 (44.4) | 213 (30.1) | |
| Medicare | 225 (45.6) | 74 (34.6) | 299 (42.2) | |
| Medicaid | 90 (18.2) | 29 (13.6) | 119 (16.8) | |
| Other Government | 12 (2.4) | 3 (1.4) | 15 (2.1) | |
| No insurance | 38 (7.7) | 11 (5.1) | 49 (6.9) | |
| Unknown | 11 (2.2) | 2 (0.9) | 13 (1.8) | |
| Income | <0.05 | |||
| <$48,000 | 233 (47.2) | 79 (36.9) | 312 (44.1) | |
| ≥$48,000 | 256 (51.8) | 133 (62.2) | 389 (54.9) | |
| Unknown | 5 (1.0) | 2 (0.9) | 7 (1.0) | |
| Location | 0.78 | |||
| Urban | 379 (76.7) | 163 (76.2) | 542 (76.6) | |
| Non-urban | 102 (20.7) | 47 (22.0) | 149 (21.1) | |
| Unknown | 13 (2.6) | 4 (1.9) | 17 (2.4) | |
| Facility | 0.62 | |||
| Academic | 244 (49.4) | 110 (51.4) | 354 (50.0) | |
| Community | 250 (50.6) | 104 (48.6) | 354 (50.0) | |
| Facility Volume | 0.12 | |||
| High volume (Upper quartile) | 99 (20.0) | 54 (25.2) | 153 (21.6) | |
| Low volume | 395 (80.0) | 160 (74.8) | 555 (78.4) | |
| Head and Neck Subsite | <0.001 | |||
| Oral Cavity | 254 (51.4) | 161 (75.2) | 415 (58.6) | |
| Hypopharynx | 78 (15.8) | 20 (9.4) | 98 (13.8) | |
| Larynx | 162 (32.8) | 33 (15.4) | 195 (27.5) | |
| Dose | <0.01 | |||
| None | 231 (46.8) | 81 (37.9) | 312 (44.1) | |
| Low (50-65Gy) | 32 (6.5) | 24 (11.2) | 56 (7.9) | |
| High (65-80Gy) | 107 (21.7) | 70 (32.7) | 177 (25.0) | |
| Unknown | 124 (25.1) | 39 (18.2) | 163 (23.0) | |
| Primary Treatment | <0.01 | |||
| No treatment | 83 (16.8) | 21 (9.8) | 104 (14.7) | |
| Surgery | 27 (5.5) | 2 (0.9) | 29 (4.1) | |
| RT | 50 (10.1) | 14 (6.5) | 64 (9.0) | |
| Surgery+RT | 5 (1.0) | 6 (2.8) | 11 (1.6) | |
| CT | 97 (19.6) | 49 (22.9) | 146 (20.6) | |
| CRT | 179 (36.2) | 96 (44.9) | 275 (38.8) | |
| Surgery+CRT | 25 (5.1) | 12 (5.6) | 37 (5.2) | |
| Unknown | 28 (5.7) | 14 (6.5) | 42 (5.9) | |
| T stage | <0.05 | |||
| T0 | 2 (0.4) | 0 (0.0) | 2 (0.3) | |
| T1 | 53 (10.7) | 18 (8.4) | 71 (10.0) | |
| T2 | 105 (21.3) | 59 (27.6) | 164 (23.2) | |
| T3 | 110 (22.3) | 37 (17.3) | 147 (20.8) | |
| T4 | 173 (35.0) | 65 (30.4) | 238 (33.6) | |
| Unknown | 51 (10.3) | 35 (16.4) | 86 (12.2) | |
| N stage | 0.15 | |||
| 75 (15.2) | 24 (11.2) | 99 (14.0) | ||
| N0 | 63 (12.8) | 28 (13.1) | 91 (12.9) | |
| N1 | 31 (6.3) | 12 (5.6) | 43 (6.1) | |
| N2 NOS | 15 (3.0) | 4 (1.9) | 19 (2.7) | |
| N2A | 103 (20.9) | 52 (24.3) | 155 (21.9) | |
| N2B | 129 (26.1) | 68 (31.8) | 197 (27.8) | |
| N2C | 46 (9.3) | 20 (9.4) | 66 (9.3) | |
| N3 | 32 (6.5) | 6 (2.8) | 38 (5.4) | |
| HPV classification | ||||
| HPV non-16-non-18 high-risk | 13 (6.1) | |||
| HPV-16 only | 123 (57) | |||
| HPV-18 only | 2 (0.4) | |||
| HPV-16 and HPV-18 | 11 (5.1) | |||
| HPV high risk not stated | 15 (7) | |||
| HPV not otherwise specified | 41 (19.2) | |||
| HPV low risk | 9 (4.2) | |||